Skip to main content

Table 3 Correlation between NEI-VFQ-25 composite score change and logMAR BCVA change from baseline

From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

   Correlation coefficient P value
3 months (N=98) Total − 0.27 0.009
Baseline BCVA below 0.5 −0.33 0.02
Baseline BCVA above 0.6 − 0.27 0.10
12 months (N=69) Total −0.31 0.01
Baseline BCVA below 0.5 −0.33 0.048
Baseline BCVA above 0.6 −0.39 0.03
  1. BCVA best-corrected visual acuity, logMAR logarithm of the minimal angle of resolution, NEI-VFQ-25 25-item National Eye Institute Visual Function Questionnaire
\